The aim of the partnership is to enhance scope of care and create avenues for new research
Pfizer India has signed a Memorandum of Understanding (MoU) with Max Super Specialty Hospitals to give fellowships to young doctors in 17 Max Hospitals to gather real-world evidence on drug efficacy and proven therapies from existing electronic patient records. This evidence generation will focus on the prevention, treatment and management of diseases that are of public health priority in India, such as cancer and cardiovascular disease. The bespoke fellowships will be a form of recognition and will enable young clinicians who want to pursue medical research to do so with clear goals in place.
The fellowship programme will provide young clinicians and researchers at all 17Max Speciality Hospitals across four states in India, with an opportunity to acquire funding and sponsorships for their research work. The selection criteria for these fellowships will be decided by the medical and research experts at Max Healthcare. Pfizer will provide technical and financial support to the programme.
Additionally, through this collaboration, Pfizer and Max Hospitals plan to build centres of excellence in rare diseases. The MAX hospital will be COE for placing various RWE studies, capability-building workshops and fellowship programmes in rare disease areas to start with.
Dr Sandeep Budhiraja, Group Medical Director from Max Healthcare, said “Real-world evidence is becoming increasingly important in healthcare decision making. It has the potential to provide invaluable insights and work in synergy with other emerging developments such as greater use of data science and genomics. Together these efforts can transform the way we look at modern medicine. It gives us immense pleasure to collaborate with Pfizer India, which has taken significant strides into several areas of cutting-edge research, to solve critical scientific problems.”
